Last reviewed · How we verify
atorvastatin, aspirin, losartan, amlodipine
atorvastatin, aspirin, losartan, amlodipine is a Fixed-dose combination: HMG-CoA reductase inhibitor, antiplatelet agent, angiotensin II receptor antagonist, and calcium channel blocker Small molecule drug developed by Russian Cardiology Research and Production Center. It is currently FDA-approved for Secondary prevention of cardiovascular events in patients with coronary artery disease or high cardiovascular risk, Hypertension management in patients requiring lipid-lowering and antiplatelet therapy.
This is a fixed-dose combination of four cardiovascular agents that work synergistically to reduce cholesterol, prevent thrombosis, lower blood pressure, and improve coronary blood flow.
This is a fixed-dose combination of four cardiovascular agents that work synergistically to reduce cholesterol, prevent thrombosis, lower blood pressure, and improve coronary blood flow. Used for Secondary prevention of cardiovascular events in patients with coronary artery disease or high cardiovascular risk, Hypertension management in patients requiring lipid-lowering and antiplatelet therapy.
At a glance
| Generic name | atorvastatin, aspirin, losartan, amlodipine |
|---|---|
| Sponsor | Russian Cardiology Research and Production Center |
| Drug class | Fixed-dose combination: HMG-CoA reductase inhibitor, antiplatelet agent, angiotensin II receptor antagonist, and calcium channel blocker |
| Target | Multiple: HMG-CoA reductase, cyclooxygenase, AT1 receptor, L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol and reduce atherosclerotic plaque formation. Aspirin irreversibly inhibits cyclooxygenase to prevent platelet aggregation and thrombotic events. Losartan blocks angiotensin II type 1 receptors to reduce vasoconstriction and lower blood pressure. Amlodipine blocks L-type calcium channels in vascular smooth muscle to cause vasodilation and further reduce blood pressure and improve myocardial oxygen supply.
Approved indications
- Secondary prevention of cardiovascular events in patients with coronary artery disease or high cardiovascular risk
- Hypertension management in patients requiring lipid-lowering and antiplatelet therapy
Common side effects
- Muscle pain or myalgia
- Headache
- Dizziness
- Gastrointestinal upset
- Peripheral edema
- Bleeding or bruising
Key clinical trials
- Feasibility Study of a Novel mHealth Application to Enable Community Health Workers to Manage (NA)
- The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (NA)
- Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- atorvastatin, aspirin, losartan, amlodipine CI brief — competitive landscape report
- atorvastatin, aspirin, losartan, amlodipine updates RSS · CI watch RSS
- Russian Cardiology Research and Production Center portfolio CI
Frequently asked questions about atorvastatin, aspirin, losartan, amlodipine
What is atorvastatin, aspirin, losartan, amlodipine?
How does atorvastatin, aspirin, losartan, amlodipine work?
What is atorvastatin, aspirin, losartan, amlodipine used for?
Who makes atorvastatin, aspirin, losartan, amlodipine?
What drug class is atorvastatin, aspirin, losartan, amlodipine in?
What development phase is atorvastatin, aspirin, losartan, amlodipine in?
What are the side effects of atorvastatin, aspirin, losartan, amlodipine?
What does atorvastatin, aspirin, losartan, amlodipine target?
Related
- Drug class: All Fixed-dose combination: HMG-CoA reductase inhibitor, antiplatelet agent, angiotensin II receptor antagonist, and calcium channel blocker drugs
- Target: All drugs targeting Multiple: HMG-CoA reductase, cyclooxygenase, AT1 receptor, L-type calcium channel
- Manufacturer: Russian Cardiology Research and Production Center — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Secondary prevention of cardiovascular events in patients with coronary artery disease or high cardiovascular risk
- Indication: Drugs for Hypertension management in patients requiring lipid-lowering and antiplatelet therapy
- Compare: atorvastatin, aspirin, losartan, amlodipine vs similar drugs
- Pricing: atorvastatin, aspirin, losartan, amlodipine cost, discount & access